Plain-English translation of NCT03046316 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Neoplasms research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying whether patients with advanced lung cancer who have a good response to their first round of treatment can benefit from additional localized therapies — such as surgery, radiation, or interventional procedures — aimed at remaining cancer spots. The goal is to see if this combined approach can help you live longer and better control your cancer.
Many patients with advanced lung cancer initially respond well to chemotherapy or targeted drugs, but cancer can still come back. This trial is testing whether adding localized treatments to target remaining spots of cancer might improve long-term outcomes beyond what initial therapy alone can achieve.
If you qualify, you will be reviewed by a team of specialists (surgeons, radiation doctors, and interventional radiologists) who will decide together whether localized treatment to your primary tumor or metastatic spots is right for you. You will then receive that localized treatment — which might be surgery, radiation, or a minimally invasive procedure — and continue regular follow-up visits and imaging scans to monitor how well the combined approach is working. The study plans to enroll 60 patients.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Guangdong Association of Clinical Trials
Enrollment target
~60 participants
Started
June 2020
Primary completion
July 2022
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2020.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
ZHEN WANG, PhD,MD
Guangdong General Hospital&Guangdong Academy of Medical Sciences